Key facts
- This page summarizes Larry Todd Edwards's Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Aug 2026, 16:25.
Larry Todd Edwards - 24 Aug 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- ORKA
- Reported as of
- 24 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Aug 2026, 16:25:06 UTC
- Prior SEC filing
- 03 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Quinlan, as attorney-in-fact for Larry Todd Edwards
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Larry Todd Edwards filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 25 Aug 2026.
Change
- Previous filing in this sequence was filed on 03 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001994805
Primary reporting owner
Edwards Larry Todd
- Relationship
- Chief Commercial Officer
- Address
- ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK
- Signature
- /s/ Paul Quinlan, as attorney-in-fact for Larry Todd Edwards
- Signature date
- 25 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORKA
transaction
Common Stock
Award
- Transaction value
- Shares
- +100,000
- Change %
- Price
- $0.000000*
- Shares after
- 100,000
- Date
- 24 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORKA
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- Shares
- +20,000
- Change %
- Price
- $0.000000*
- Shares after
- 20,000
- Date
- 24 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $102.42
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter.
Footnote F2
The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter.